The GUF1 Knockout NCI-H1975 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population in which GUF1 gene function has been disrupted in the NCI-H1975 human lung adenocarcinoma cell line. This polyclonal knockout model introduces heterogeneous loss-of-function mutations, providing a genetically diverse system to study mitochondrial translation and oxidative phosphorylation (OXPHOS) without clonal selection bias.
The NCI-H1975 host cell line is a widely used model of EGFR-mutant non-small cell lung cancer (NSCLC), harboring both the L858R activating mutation and the T790M resistance mutation. These cells recapitulate key features of lung adenocarcinoma and are extensively employed in studies of EGFR-targeted therapy resistance, cancer metabolism, and tumor biology.
GUF1 encodes a mitochondrial GTPase that mediates ribosome recycling during mitochondrial translation. It functions downstream of the PGC-1??/NRF1/TFAM transcriptional cascade and interacts with mitochondrial ribosomal proteins (MRPL, MRPS) and translation factors TUFM and GFM1. GUF1 activity is essential for the synthesis of mitochondrial DNA-encoded OXPHOS subunits, including MT-ND1 (complex I), MT-CO1 (complex IV), and MT-ATP6 (complex V). Loss of GUF1 disrupts mitochondrial ribosome recycling, blocking the translation of these core subunits, impairing OXPHOS assembly, and triggering a mitochondrial stress response.
In EGFR-mutant NCI-H1975 cells, GUF1 knockout provides a powerful tool to dissect the role of mitochondrial protein synthesis in cancer metabolism and drug sensitivity. These cells may exhibit increased dependence on mitochondrial ATP production, and the knockout model enables interrogation of OXPHOS inhibitor sensitivity (e.g., IACS-010759) and potential synergistic effects with EGFR inhibitors. Activation of retrograde signaling and metabolic reprogramming can also be investigated in this context.
The polyclonal GUF1 knockout cells are suitable for a variety of readouts, including western blotting for OXPHOS subunits, RT-qPCR for mitochondrial gene expression, and RNA-seq for transcriptome analysis. Seahorse bioenergetics assays can quantify changes in oxygen consumption, while cell viability and apoptosis assays with OXPHOS inhibitors assess drug sensitivity. These applications support research into mitochondrial translation defects, combined OXPHOS deficiency, and metabolic vulnerabilities in lung cancer. For further information, contact Ascent Research.
